Ortho Biotech Oncology Research & Development, a unit of Johnson & Johnson, said Thursday it unblinded late-stage study data of a potential prostate cancer drug, citing the treatment's effectiveness.
A blind experiment is designed to prevent any possible "placebo effect" or bias. Once the analysis is complete, the data is allowed to be "unblinded."
The company is studying abiraterone acetate plus prednisone for the treatment of patients with metastatic advanced prostate cancer, also called castration-resistant prostate cancer.
The study involves 1,195 patients whose disease has progressed even after treatment with one or two chemotherapy regimens.
The results will be presented at the upcoming European Society of Medical Oncologists meeting, which is held in Milan between Oct. 8 and Oct. 12.
**Published by AP
No comments:
Post a Comment